Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning and welcome to BioArctic AB's presentation for the second quarter. It's very exciting times for BioArctic. Today, I have three key messages to share. The first one is that Leqembi sales are increasing. It's starting to take off in the US. It's going over expectations in Japan. It's also started really well in China. The second message is that the regulatory processes for Leqembi continue, and we are now approved in eight different geographies, representing more than 80% of the expected market for Leqembi. The third message is that the rest of our project portfolio is progressing really well, and we are preparing for the Phase 2a study in Parkinson's disease. Next slide please. I'm Anders Martin-Löf, the CEO of BioArctic. And I will share today's presentation with our CFO, Anders Martin-Löf. We also have our CMO, Tomaso, here again for the Q&A session. Um, after the presentation. Next slide please. This is our disclaimer. BioArctic is listed on the Nasdaq Stockholm Large Cap. Next slide please. A lot has happened during and after the second quarter, and I will start with Leqembi, where we are involved in many regulatory activities. Our partner Eisai has had two regulatory submissions to the FDA in the USA. They have submitted a supplemental BLA for intravenous maintenance dosing with less frequent dosing, which means once a month dosing. Eisai has also received fast track designation for the subcutaneous administration. And then they have initiated a rolling submission for a new BLA for the subcutaneous auto-injector for maintenance dosing. We have received several regulatory approvals in South Korea, Hong Kong, Israel, United Arab Emirates, and last week also in Great Britain. We had a drawback in July when the CHMP adopted a negative opinion on the market authorization for Leqembi in the EU. Our partner Eisai has requested a re-examination of the opinion. Leqembi has, as I said, also been launched in China and it was initiated at the end of June in a very good way. We have long-term data which has been requested for some time, and that was presented now: three-year data with Leqembi at the Alzheimer's Congress, AIC, and this showed continued increasing benefit for the patients with a maintained safety profile. If we then look at Exidavnemab. Phase two: Two phase one studies were published with the results in the Journal of Clinical Pharmacology, and data showed that Exidavnemab was generally well-tolerated and had an excellent PK profile, with an elimination half-life of about 30 days, and this supports monthly dosing. And I think this is great news in preparation for the phase 2a study that is starting later this year. If we look at other projects in our portfolio, they are also progressing well. And we have the first agreement signed for our brain transporter technology during the quarter, where Eisai and Biogen entered into a research evaluation agreement regarding the drug candidate. BioArctic AB's next slide, please. Leqembi is the first disease-modifying Alzheimer's disease treatment, which is now approved in eight different markets around the world. It's on its way to establishing a new standard of care for patients. And this slide shows the situation of Leqembi globally. If we look at the US first, I have mentioned the two submissions with less frequent intravenous administration. Dosing, where the scheduled date set by the FDA for the subcutaneous auto-injector maintenance dosing is the 25th of January next year. Launch is ongoing in the US, Japan, and also in China, and we will talk more about that later in the presentation. And as I said, we have received several approvals in other parts of the world. South Korea, Israel, Hong Kong, United Arab Emirates, and recently Great Britain. The Great Britain authorization was great. I was really happy to see that, especially since the European CHMP gave a negative opinion in July. And Eisai has, as we said, requested re-examination and the outcome is expected later this year. So, next slide, please. As I presented this slide during our partner's quarterly report, we start with a regulatory update for the EU. There are three parts. The first one is that the protocol and the statistical analysis method for the Phase 3 program were determined in advance, and it was in consultation with regulatory authorities, including the EU regulatory authorities. The second part is with regard to the benefits, and in the phase three study period, Leqembi met the primary endpoint as well as all key secondary endpoints with high statistical significance. Furthermore, long-term data for up to three years have shown maintained benefits over that period. The third aspect concerns the risks and side effects called areas. At the Alzheimer Congress, it was concluded when long-term data was presented that the risk for the area is highest in the first six months and very low thereafter, and most cases are asymptomatic. I think it was reassuring to hear the presentation on the side effect profile and real-world evidence. It was also concluded that it can be well managed in accordance with the guidelines. The CHMP opinion was surprising to us and I think very disappointing. And of course, we hope for a positive CHMP opinion later this year, followed by an approval in Europe early next year. We draw strength from the firm support that has been shown for Leqembi from both researchers, opinion leaders, and patient organizations across Europe. Many of them are now taking a stance and ensuring that their voices are being heard. Next slide.
Positive news came last week when Great Britain authorized Leqembi. I want to point out that there was a slight difference in their approval from what has been seen in other countries. They focused on lowering the risk of area, which is the main side effect of concern. The indicated population therefore excluded individuals who are ApoE4 homozygous, meaning they possess two alleles of ApoE4. This is a specific genetic variant, which implies a higher risk of developing Alzheimer's disease earlier, as well as an increased risk of experiencing side effects. Homozygotes comprise about 10 to 15% of the Alzheimer's population. The indication that was authorized includes early Alzheimer's patients who are ApoE4 homozygous, which means they have two ApoE4 alleles, or are non-carriers. They have no ApoE4 allele. This represents the vast majority of Alzheimer's patients. If we look at the indicated population in the phase three trial, Leqembi showed slowing of clinical decline over 18 months, compared with placebo by 33% on CDR-SB scores. As you can see on the graph to the right, it was 39% on the activity of daily living scale. It was also observed that there was a lower frequency in area E of about 9%, and the symptomatic area was about 2% in this population. In Great Britain, a consultation process involving ASI and other stakeholders will now take place before Leqembi can become available for use in the national healthcare system. The reimbursement authority called CMS. Their draft recommendation was that cost-effectiveness did not support routine use. The authority has requested additional information before making its final decision. ASI has stated that they will work collaboratively with Eisai to make progress. It can be available to eligible patients living with early Alzheimer's disease as soon as possible. Next slide, please. I want to share some key highlights from AIC, which is one of the largest Alzheimer's conferences, held in Philadelphia in July this year. Long term clinical data has been requested for Leqembi. And now, as I presented three-year data which showed increased patient benefit with maintained safety profiles. If you look at the graph to the left, we can see a clear and meaningful long-term effect over 36 months, where all patients have received Leqembi either from the start, which amounts to three years, or after they had their 18-month placebo treatment in the course study, followed by 18 months of treatment with Leqembi. There are two points I want to highlight on this graph. The first point is that the benefits increase over time. We can see that the benefit was 0.45 after 18 months, and it doubled to 0.95 after three years. The second thing I want to point out is that patients benefit more if they start treatment early. So if you look at the top green curve, you'll see that it indicates more benefits. But you also see that the middle curve, which starts black, represents the placebo. After 18 months, it's green, which means that they have got Leqembi. Then you see that they also benefit from the treatment in comparison with the purple curve, which is the control from the ethnic group, matched to the study. And this is from a small substudy in patients with no or very low tau in the brain. And this means that they are early in the disease. We see that 60% of these patients had improvements after 18 months, indicating they were better than when they started the treatment. More than 50% of the patients were still doing better after three years. I think we should be a little bit careful since this is only 40 patients, but I think it's encouraging and further emphasizes the importance of starting treatment early. I also want to say that safety matters, and it was reassuring to see that no new safety findings were reported and the very low frequency of errors was reported after the first six months. And now thousands of patients have been treated. Um, I think this is reassuring. Key opinion leaders from both the US and Japan. They concluded that the side effects are manageable and that the real world evidence data showed a lower frequency than has been reported in clinical trials. It was also emphasized that continuation of treatment is important even after the plaques have been removed from the brain. And this was demonstrated by data on biomarkers which start to deteriorate if treatment stops, whereas continued benefit was shown for when treatment was continued. Next slide, please. There has been a lot of discussion about whether the effects of Leqembi and this kind of treatment are clinically meaningful, and I just want to explain a bit about the scale that is being used in these kinds of clinical trials. It's called CDR sum of boxes. This measures cognition and function with three items each. The cognitive items are memory, orientation, and judgment or problem solving. The functional items are community affairs, home and hospice care, and personal care. Sometimes I hear that a 0.5 difference on an 18 point scale is not clinically important, and to me, that is just completely wrong. I think that for a patient, 0.5 could mean a difference from having a slight impairment.
Um.
To being unable to function independently on one of the items on this scale. And no one can convince me that that's not meaningful for a patient with this devastating and deadly disease. What we hear that patients want is longer time to enjoy life with their loved ones, especially in the less severe stages. And Leqembi has shown an average saving of about 5.3 months already after an 18-month treatment. And this is longer if treatment continues. So I think the effect is a clearly meaningful benefit for the patients. Next slide, please. The development continues. And both with the IV maintenance dose which is less frequent than once a month but also subcutaneous with an autoinjector to make it more convenient for patients and to be able to make its administration easier at home. I think it is also great to see how the blood-based biomarkers for diagnosis will simplify the patient journey and help identify patients in a much easier way. Um, in contrast to PET scans and CSF tests, which sometimes can be challenging, this development with blood-based biomarkers proceeds faster and better than I had expected. Professor Oskar Bosson from Sweden. He presented data at the Alzheimer's International Conference on blood-based biomarkers with 90% accuracy in diagnosing Alzheimer's disease. This is remarkable. It's better than both primary care physicians and even specialists. And I think this is important for the opportunity to diagnose patients earlier and on a broader scale. This is already being used, for example, in China, and it's being piloted in Sweden and in many other countries at the moment. Treatment earlier has, as I said, shown more benefits, which is encouraging for the phase three study known as AHEAD 345, currently ongoing in subjects without symptoms but with elevated amyloid deposits in the brain. This study already uses blood-based biomarkers to identify the right patients. And the recruitment for this phase three trial is expected to be completed this year. Next slide please. So, I've been talking a lot about Leqembi and Exidavnemab. But I want to say that BioArctic is of course more than that as well. We have a broad project portfolio for the treatment of neurodegenerative diseases. And our programs have progressed well. And we're very pleased with the first agreement in place for our brain transporter technology. The Eisai collaboration with BAND 2802 is to evaluate this asset. I also want to point out that BAND 2803, which is another Alzheimer's program utilizing brain transporter technology, looks promising and we plan to present data from this program later this year. Our Parkinson's disease program is actively preparing to start phase 2 next quarter. Next slide.
Please.
We think that our alpha-synuclein portfolio has many opportunities in various known neuronal synucleinopathies, such as Parkinson's disease dementia, Lewy body dementia, and more advanced stages, as well as the orphan indication multiple system atrophy. I think it's reassuring that biomarkers are available to identify the right patients with pathological alpha-synuclein, and we will also use these in our phase two study. Next slide please. The phase 2a study with Mab is called EXIST. And it will be conducted on patients with mild to moderate Parkinson's disease. The design is a randomized, double-blind, placebo-controlled trial with a low dose and a high dose compared to placebo. The primary endpoint will be safety and tolerability, and the secondary endpoints will be pharmacokinetics and immunogenicity. Several biomarkers will be explored, including biochemical biomarkers as well as digital and cognitive markers, which are relevant for patients and will also be an important preparation for the next proof of concept studies. So, there is a lot of activity happening at BioArctic at the moment in order to initiate this study later this year. Next slide.
Please.
With that, I will hand over to Anders Martin-Löf for the financial summary.
Thank you very much, Neela. Uh, starting with the royalties, we are very happy to see that the Leqembi royalties are continuing to grow, actually at an exponential rate. The global sales were ¥6.3 billion. That is roughly $40 million. That's roughly 120% higher than the quarter before. And the royalties, they increased to 42.6 million Swedish krona. That's a doubling from the quarter before. Or if you look at annual figures, it's a 70-fold increase year over year. That's 7,000% if we're talking percent. So really, we are seeing really high growth numbers. That's mainly driven by the US market. And we are really happy to see that the US expansion started picking up speed during this quarter. As you may recall, the first two quarters after the launch, in the second half of last year, it was fairly slow for US clinics. They were struggling a little bit to get the infrastructure together and start treating patients. That started to happen towards the end of the year and in the first quarter, they were starting to treat patients more on a pilot scale. What we saw now in the second quarter is that they are really scaling up now. They're starting to treat a lot of patients. And that is then further supported by a larger commercial infrastructure by Eisai and Biogen. They have increased by roughly 30% and now have 450 positions in place. And that helps to increase the number of sites that are starting to treat patients. So it was very reassuring to see that the number of hospitals that started ordering can be increased by 40% in the second quarter over the first quarter. All in all, this means that we saw a significant increase in sales during the quarter. So the April sales for 0.9 billion GM grew to 2.1 billion in June. That means we went from 6 million per month in April to $13 million per month in June, so in total $30 million. So now I would say that we're on a really good trajectory in the US. It took a little bit longer than was initially expected when the product was launched, but now things start to look really good in the US. We also saw a very strong start in Japan, with roughly $10 million in sales already in the second quarter after the launch. We did not see the sluggish implementation that we observed in the first two quarters in the US. Already now, 500 facilities have started prescribing out of the 650 that had implemented the pathway at the end of the first quarter. And then you should bear in mind that of the 800 doctors that have started prescribing, only 70 have started prescribing to large numbers of patients. And that will, of course, increase in the coming quarters. So we know that growth will continue to be very strong in Japan. The launch in China was also mentioned by Gunilla Osswald. That's also a really interesting market. That happened a little ahead of time. And here Eisai is adopting a really interesting model with using an online platform and blood-based biomarkers. So potentially this could be a model for how to handle this in the future. And the rest of the world. China really has a large potential. Initially, Eisai is targeting the private market, which is relatively large in China. In the long term, Asia expects China to become an even larger market than Japan. It will be incredibly interesting to see how this develops in the coming quarters if we turn to the next slide. This high growth is expected to continue, according to ACI. They issued a forecast at the end of their fiscal year where they expect that they can grow from roughly $30 million in 2023 to $360 million in 2024, so that's more than a tenfold increase. In their last quarterly earnings call, they stated that their performance was according to plan or even better in certain markets. So they still expect to see these numbers. This corresponds to royalties of roughly 400 million Swedish krona, from the second quarter of 2024 to the first quarter of 2025. And those are really big numbers for us. But you should remember, this is still only the beginning. Asia is expecting a fivefold increase from 2024 to 2026. So, if that comes through, then they would be selling for roughly $2 billion in 2026. So of course, it's hard to tell exactly what will happen. But Neil has mentioned that there are a lot of developments that will underpin this. You will see a much easier administration with the subcutaneous version coming out in the coming years. And I also believe that we will see the blood-based biomarker diagnosis being implemented in that time period. So, we firmly believe that this market is set to grow immensely over the next few years. If we then turn to our finances, looking first at the net revenues on the left-hand side, they have been very lumpy in the past due to the milestone payments that have occurred from time to time. For this quarter, we had 50 million in net revenue, 50 million Swedish kronor. There were no milestone payments in this quarter, and I think it is unlikely that we will see any milestone payments during this year. The one mention that could happen is if we get approval in the EU. But if you receive positive feedback in the May timeframe, it will probably take a month or two for the European Commission to grant permission. To give their full approval. So it's unlikely that we will see that milestone this year, even if it can be approved in Europe. Over time, the two new revenue streams will shift the revenue mix. They will not see this lumpiness in the future. You saw royalty revenue of $43,000,000 in the second quarter and core promotion revenues of $3 million. If we receive approval in Europe, the promotional revenues will continue to increase over time. And we have already talked about the royalties. They will increase over time and this will be rapid. If the forecast for 2024 is correct, we are to expect roughly 360 million Swedish kronor in royalties over the coming three quarters, i.e., roughly an average of 120 million kronor in royalties per quarter, probably less in the next quarter, but higher in the first quarter of 2025. So I think you will see a major shift in these curves over the next three quarters. If you then look at the operating expenses on the graph, you see that they grew to 121 million Swedish kronor, up from 104 million in the second quarter. The majority of this is comprised of R&D expenses. They grew to 84 million Swedish kronor, up from 41 million a year ago. So, there's a significant increase there, and this is exactly what we aim to do. We are focusing a lot of resources on our portfolio and are trying to accelerate our programs as much as possible. We also saw an increase in marketing and sales costs to 60 million from 10 million a year ago, and this cost increase quarter over quarter will continue throughout the remainder of the year, mainly in the R&D department, where we are progressing our product portfolio successfully, starting a Phase 2 clinical trial. And we're preparing other programs for INDs as well. We will also see increased activity in the commercial organization, but here we are being very cautious. We are not expanding our organization until we have a final group opinion. We have previously stated that we expected the total cost for 2024 to increase by roughly 30 to 50% compared to 2023. That's still accurate. We will probably be somewhere towards the middle of that range in 2024. On the right-hand side, you see that our operating loss was 76 million for the quarter, roughly in line with previous quarters. If we turn to the next slide and look at the left-hand graph, you see that the net result, a loss of 68 million, is slightly better than the operating loss of 76 million. That's mainly driven by strong financial net results. The cash flow, as seen in the middle graph, is slightly worse than the operating loss, being 94 million compared to the 76 million operating loss. And that's primarily driven by our growing accounts receivable. Due to this, the royalties that we receive from partners are paid 120 days after the end of the quarter. So you will continue to see this lag between cash flow and revenues as long as the royalties keep growing significantly. Then on the left-hand side, you see our cash balance. We had roughly 890 million Swedish kronor in cash and short-term investments at the end of the second quarter. It's still a very solid position that is roughly six times our quarterly costs. So we're very well funded. However, towards the end of the year, we have previously said that we expect to have cash between 800 and 900 million. That will probably not be the case, since we will likely not receive the payment of the EU milestone. So, I think we will be roughly in the range of 600 to 700 million instead. However, this is really not dramatic. We still think there is a very good chance that Leqembi will be approved in Europe and that we will receive that milestone. And even more importantly, we expect to be profitable from next year. Since we see that the cannabis sales are really on a good trajectory. We still stand by that guidance, I would say. So all in all, we're doing really, really well. We are really happy to see that the trajectory is now very positive. And with that, I leave the floor back to Gunilla for some closing remarks.
Thank you so much. So, next slide please. So, if we look into the fourth quarter of this year, we plan to start the Phase 2a study in Parkinson's disease with Exidavnemab. And we're looking forward to presenting some data on our brain transport program. That's something I'm really looking forward to as well. BioArctic AB plans to complete the rolling submission of Leqembi with a subcutaneous autoinjector to the FDA. We look forward to the reexamination in Europe and hope for a positive opinion from its committee during the fourth quarter of this year. We also hope for more potential approvals of Leqembi that could also come later this year and next year. So, I think there are a lot of exciting times ahead for biotech. Next slide.
Please.
To summarize today's presentation, Leqembi is approved in eight geographies and now launched in the US, Japan, and China. And if you consider this, it's the considerably large patient populations with early Alzheimer's disease that can now benefit from the treatment. And even a small portion of those populations will be substantial. And I think it's very gratifying, gratifying that we can help many patients. The launch is starting to take off, as we heard from the founders, and it will be exciting to see more and more patients being able to access Leqembi treatment. We're hoping for more approvals, and Eisai continues with more regulatory applications and further development of Lecanemab. Our pipeline is progressing really well, and the first brain transporter agreement has been signed, and we are looking forward to phase two, a start of the exit ramp. Our finances remain solid, and we have almost 0.9 billion Swedish kronor in the bank. I think it's great so we can focus on driving the projects forward towards patients. Next slide please. So by that we say thank you for your attention and we're happy to take some questions.
And before we take questions I have two remarks I want to make on the presentation. One is that when Gunilla mentioned the indicated population for the UK, for Great Britain.
She obviously meant heterozygotes and non-carriers and nothing else. And when Anders mentioned when a potential CHMP positive opinion could come, he obviously meant November time frame and not May time frame. Thank you. Now we can take questions.
Thank you so much for that at all. Thought corrections. Thank you so much, Oskar. Now we're happy to take questions.
If you wish to ask a question, please dial hash five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial hash six on your telephone keypad. The next question comes from Victor Sundberg from Nordica. Please go ahead.
Yes.
Hi, guys. Thanks for taking my questions. So one on the pipeline project. Um, so there was a paper out in JAMA Neurology a week ago or so looking at postmortem brain tissue for patients with Down syndrome. And they found that, uh, I guess we already know that, but that cerebral amyloid angiopathy is more present in these patients, and that they kind of are bound to blood vessels in a degree that concerned these researchers in that paper, that these findings in any way impact your priority of the pipeline project in Down syndrome from your part. And secondly, in, in the European regulatory approval process. I know it was driven by Eisai, but I just wonder if you perhaps heard that they discussed APOE for double allele exclusion previously, and if based on those discussions, that it would be likely that the CHMP would be more likely to reconsider its negative opinion on the compound if this group was excluded as it was in the UK approval. Thank you.
Thank you so much, Victor. I'll start with the second one. And of course, it's a senior partner, Eisai, who is driving the regulatory discussions. And I think they need now to take their place. So we will not comment on anything about what has been discussed and not discussed and so forth. We just now have to wait and see how the process unfolds. And I think that there are many different approaches you can take in this matter. I really hope it will result in a final positive opinion in the re-examination. And then, returning to your first question about Down syndrome. We have Thomas in the room, and he has also been presenting biotech data on Down syndrome, where we have shown that Leqembi also can bind and seems to be a good possibility for these patients. We are aware that they have a higher risk of cancer in this patient population. And I think we also know that subcutaneous treatment is important for these patients. Thomas, would you like to comment?
I think it's absolutely correct to say that this is a vulnerable patient population. And when introducing them to such a population, we really want that it be done in the optimal way, at the right dose, and with the right modality. Subcutaneous administration, in all likelihood, is a better way to proceed.
Thank you very much.
Thank you.
Victor,
The next question comes from Cecilia Hernandez from Van Kempen. Please go ahead.
Yes.
Thank you for taking our questions. This is a question for Luisa concerning your brain transporter technology. Could you elaborate on what we can expect from the updated plans in Q4 this year, or anything you can already share in advance on how it compares to Roche's brain shuttle? How long will it take to get approved? Thank you.
Thank you so much for the question. As you know, I'm really excited about our brain transporter technology that we have now applied to several of our internal programs. It has some similarities. With the Roche brain shuttle, it also shows some important differences that we will discuss more in the next quarterly report, where we hope to also present some preclinical data. We have data, and they appear really promising and exciting. And we are receiving data now every day. So I think the next quarterly report will be a good time point. It will, of course, be preclinical data that we will be able to present. We are preparing with IND-enabling activities, for example, for BAND-2803, in order to transition it towards the clinical setting.
Okay. Thank you.
Thank you. The next question comes from Rajan Sharma from Goldman Sachs. Please go ahead.
Hi. Thanks for taking my questions. Just on the sBLA re-examination, and I realize this is managed by your partner Eisai, but could you confirm if there are any new data which can be included in the reexamination, versus what was included at the original filing? And then maybe just one for Anders, in terms of profitability, you've obviously reiterated guidance for profitability next year. Just to confirm, is this irrespective of the European approval? And then just on Ban 2803, could you just remind us of the differentiation there relative to 2802? And how do you think about both of these assets potentially coexisting? What should we expect in terms of data before the end of the year? Thank you.
Okay.
The first question was the sBLA re-examination. It depends on the questions and the discussion that Eisai will have. So, I think that would be a good opportunity for the EMA to do a full review of all the data. Then your second question was with regard to profitability on this.
Yes.
Yes. I believe it would be profitable, given that the forecast for the sales that we have seen, if that comes through, we should be profitable regardless of what happens in the European Union.
And then your third question was 2802 and 2803. And then for 2802. It is in collaboration with Eisai. It's an undisclosed target for Alzheimer's disease, so I can't talk about that one. What we can say is 2803 is an antibody towards beta-amyloid with the brain transporter technology. So that's a possibility then to see that mechanism of action has already shown good efficacy in Alzheimer's patients. By adding brain transporter with the transferrin receptor, which also has been shown to have a very strong effect in clearing plaques, we think that this kind of treatments has a really good chance of being able to help patients going further. The data that we hope to show, that we plan to show in the next quarter will be more about how the brain transporter functions and preclinical data. So stay tuned. Looking forward to the next quarter.
Okay. Thank you.
The next question comes from Eric Hoggard from Carnegie. Please go ahead.
Hi. Thanks for taking my questions and congrats on the progress. I have a couple, if I may, first for Anders. What were the costs for the Nordic Commercial Organization in the second quarter? And has the CHMP opinion changed your investment plan in any way for the Nordic infrastructure? And then, maybe, two questions, perhaps for Gunilla or Thomas on the CMS examination. Just a follow-up on the previous question: could you confirm whether the RC data, 3D data, and real-world safety data could be submitted in the re-examination? The way I understand the process is that new data can't be submitted during the examination process. And then finally, on any potential impact that you're seeing on Leqembi in the US following the approval in July, if you have heard anything from partners. Thank you.
Could you repeat the last question? I missed the last one.
Yes, the last one was the Lilly approval in July. In the US, are you hearing anything about the potential impact from your partners?
Okay, so I think if we start from the bottom.
Yeah, let's start with the exciting stuff. And maybe I should start. Yes, I'll just jump in with marketing and sales costs that were $15.5 million in the second quarter. You were asking if the camp decision has changed our plans. Yes, a little bit. If things had been going according to plan, we would have now recruited a larger sales force, actually. Thus, we are exercising caution. However, the structure that we have is strategically very solid; we have all the strategic positions in place, and they're working extremely hard to prepare the market for the introduction of the can be, regardless of all the discussions around the camp. We just have to assume that it's going to happen. We think that's the logical outcome. So we have to prepare for that. Of course, that may be in vain in the worst case. But we keep on working. But we foresee slightly lower costs going forward in the next quarter or so. But hopefully, we will accelerate a little bit later. So, that's what we're planning for. I hope that answers the question.
So Thomas, do you want to comment on the CMS examination? Yeah.
Please provide the transcript you need editing for.
Well, I think we should really address our appreciation of ACI. I mean, they have been very conscientious, providing a lot of data for the CMS review. So in our opinion, as CMS already has access to very good insights regarding the long-term effects of Leqembi. So we are confident that this information is already accessible to them.
And then, regarding your last question about Lilly's approval in July and its impact, I think, as I've said before, we welcome more alternative treatments on the market which will help to build the infrastructure. And I think that brings a possibility to grow the market significantly, which is much needed when introducing a new kind of treatment. I mean, previously, there were mainly symptomatic treatments available on the market. Building the infrastructure for disease-modifying treatments really benefits from having more alternative treatments. So far, I think that everything looks really good for the economy, which also stands very well on its own merits.
All right. Thank you so much.
Thank you, Eric.
The next question comes from Joseph Hedden from Arc Securities. Please go ahead.
Good morning. Thanks for taking my questions. You mentioned that the China launch of Exidavnemab is using blood-based biomarkers. Could you just confirm if you know which product is actually being used, what diagnostic product, and what are the barriers to using blood-based biomarkers in major markets, like the US? Where are we seeing more use there? And then, secondly, on the web, it was good to see the publication there. Could you confirm whether you're going with the subcutaneous or an intravenous (IV) dose in the phase 2 trial? Thanks.
Let's start with your last question about Exidavnemab: as you saw in the publication, we had both IV and subcutaneous, And in this phase 2 study, it would be IV. But of course, we have an interest in developing a subcutaneous formulation for the future as well. As for the blood-based biomarkers, I don't know. Do you want to take that question, Thomas?
Well, I don't have any specific details on what exactly is being used in China. From my understanding, in terms of application in major markets, we can expect that there will be several options provided by several companies. And it's more a case of whether you have the capability to put the volume in place. So you really have the reliability at the given analytical facility where you're sending your samples. I think that is the hurdle you need to overcome. As Gunilla mentioned, we do have scientific evidence that this will work very well. It's now up to the healthcare system to implement it in a reliable fashion.
At the IC, it was mentioned that the pilot programs are active in various parts of the world, including Sweden, and they are drafting new guidance. And it is crucial to have that agreed upon before it can be utilized on a larger scale. But I think it looks really promising. And we are also using it in ahead Phase 3 trial for presymptomatic subjects, which is ongoing. So I think we will see blood-based biomarkers being used increasingly. And I think that's a great step forward for the diagnosis of Alzheimer's patients.
Okay.
Thank you.
There are no more questions at this time. So, I hand the conference back to the speakers for any written questions or closing comments.
Thank you; we have received a few written questions. I'll try to hand them out to the appropriate person. First off, there are a couple from Redeye, addressed to Frederick. Let's start with those. There was one about the CHMP reexamination process, and I think Thomas and Janet already answered that about the use of new data, etc., but maybe we can discuss the other two. Can we say anything about the rapporteurs from the first process, not the reexamination process, but the initial opinion? Can you say anything about that? And secondly, regarding Azercell's sales projections for fiscal year 2024. Could you confirm whether these could be impacted by the EU process? And maybe that's something for Anders to address.
And so, if I start then with the CHMP rapporteurs. In the first round. I get this question a lot and it's something we are trained to usually not disclose. But since the Swedish MP has publicly disclosed through media that it was France and Denmark, I believe that's now public information. Otherwise, I would not have revealed that as that's how I'm trained.
So that answers that question. Anders, can we discuss the EU.
The EU's share of the 2024 forecast for Asia? Yes. They have communicated that out of the $360 million forecasted for 2024, $280 million is expected from the US and $65 million from Japan. So, that's $345 million. So, $15 million out of the $360 million are expected to come from other markets, mostly China, I'd say. It has a very minor impact on the 2024 forecast. The numbers expected were really low. Yes, that could have a very slight impact, but it's very minor.
And Frederic, I think we can add that this largely has to do with the processes in Europe. Right, because when you get approval in Europe, that could have happened at the earliest in September. Then, you have just a few months left of the fiscal year. And in Europe, after an approval, that's when you start discussing prices with authorities in different countries, such as Germany. I think Austria can start selling right away. But the rest of the market needs price discussions before implementation. So that also means that the sales from Europe weren't really expected to start coming in until the next financial year. Um, and we had another question relating to the EU. I just want to say anything about the forecasts or the numbers that we have seen externally as to how much the total potential of the EU over time could add up to, according to the best of our knowledge right now.
Yes, the impact of the EU has been described for both 2026 and 2032. Basically, they have been saying that in 2026, they expect roughly 6% of the revenue to come from EMEA. That's the EU plus UK plus the Middle East. Well, it's going to be less than 6% for 2026. And that share was going to grow until 2032, where it was supposed to be 14% for EMEA. Less than 14% in 2032. So, a very minor difference if we do not see approval in the European Union in 2026, more sizable for 2032, but we still expect to have more than 85% of the market left in 2032, even if they may not change their opinion.
Thank you. Then we've got a question on the US market. As a statement here, private insurers seem reluctant to finance subscriptions. And U.S. neurologists seem to be somewhat divided in their view on the product. Can you make any comment on that? I think we saw something else when we attended the AIC this summer. I don't think the last statement holds, but please give us your comments.
No, I think what we have seen is, CMS, they make reimbursement through programs like Medicare. And there are many different insurers taking various stands. The veterans were the first to come out supporting the treatment of Leqembi. So, I think insurers differ in their approach. They make their own judgments. And, uh, what we heard from the US neurologist, I mean, there are always some who are negative. That's always the case when new treatments emerge, with some individuals being positive and others negative. What we really heard when we were there at the Alzheimer's Conference in Philadelphia this summer was the presentations by, for example, one professor from Columbia University in the US who had treated patients exactly according to the label, presenting data from 122 patients. And there was a Japanese professor who also had quite a lot of experience with real world evidence data. And they concluded that there were fewer side effects in the treated area. Then there was a significant observation in the clergy study. Um, similar or fewer in their experience. And no other new, um, important adverse events were reported. So I think that also after those presentations, I heard physicians coming up to the microphone and saying, I've been a bit reluctant, but now I'm convinced and I'll go home and help my patients. So I think that it's kind of a usual situation when new treatments come out; physicians need to really understand the benefits and the risks, and it's really important that it's managed in the best possible way. So, the patients get the most benefit out of the treatment. So, I think that the more we hear that the physicians use Leqembi, the more they also, um, gain the experience and learn how to use it in the best way for the patients. So I think we have a really positive path ahead of us with more patients.
And I can just add when it comes to insurance and coverage in the US, as Gunilla mentioned, the Veterans Health Association and CMS, I think I remember numbers that the total reimbursement coverage in the US is above 90% if you look at the total. So I think, you know, with access to more than 90% of the market, we're in a good place there.
Thank you, Oskar. Good job. That was the question about 2802. And I've said that I cannot say much about 2802. What I can say is that the main difference between Leqembi and donanemab on the market is, of course, that this one incorporates a brain transporter. And the thing with our brain transporter is that it utilizes the transferrin receptor to actively transport the antibody into the brain. And what we see then is that we achieve a fast, broad, and deep distribution, which I think could lead to potentially even better effects and fewer side effects because it goes into the brain differently, most likely allowing us to administer lower doses. So I think that's a very, very interesting next generation. Now I'm so happy we have Leqembi that can help patients in many different parts of the world. And then I think it's great that we are working on next-generation treatments that hopefully can help patients in the future.
Thank you. Gunilla. That was the last written question. Um, I don't see any other questions in the queue, either on the phone. So I think that concludes today's call. Thank you to everyone who has listened in and see you again next quarter.



















